Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06907251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dapagliflozin for Long COVID Syndrome

Study acronym: DALCO
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Apr 1, 2026 to Sep 1, 2026v4
  2. Re-verified, no change to tracked fieldsv3
  3. Start date: Jun 1, 2025 to Apr 1, 2026v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
Trial Details
NCT Number NCT06907251
Lead Sponsor Ottawa Heart Institute Research Corporation
Conditions
(from sponsor)		 COVID - 19, Long COVID Syndrome, SARS CoV-2
Related terms COVID-19
Enrollment 192 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov